

National Pharmaceutical Industries Company SAOG
Financial statements for the year ended 31 December 2016

Statement of comprehensive income

	Note	2016 RO	2015 RO
INCOME			
Sales	4 b)	13,223,243	10,611,548
Cost of sales	17	(7,860,127)	(6,436,608)
Gross profit		5,363,116	4,174,940
Other income	18	87,480	53,471
		5,450,596	4,228,411
EXPENSES			
Product development costs		216,584	101,231
Salaries and employee related costs		462,370	409,412
Depreciation	5 b)	44,221	38,446
Administration and selling	19	2,867,134	2,253,275
Finance charges	21	343,235	255,913
		3,933,544	3,058,277
Profit for the year before taxation		1,517,052	1,170,134
Taxation	22	(196,882)	(116,529)
Net profit and total comprehensive income for the year		1,320,170	1,053,605
Basic earnings per share	25	0.026	0.021

Note:

The Company does not have items under other comprehensive income.

The attached notes 1 to 30 form part of these financial statements.